Featured Research

from universities, journals, and other organizations

High Triglyceride Levels Common, Often Untreated Among Americans

Date:
March 30, 2009
Source:
JAMA and Archives Journals
Summary:
High concentrations of blood fats known as triglycerides are common in the United States, according to a new article. Lifestyle changes are the preferred initial treatment for hypertriglyceridemia (the resulting condition), but physical inactivity, obesity and other modifiable risk factors remain prevalent.

High concentrations of blood fats known as triglycerides are common in the United States, according to a new report. Lifestyle changes are the preferred initial treatment for hypertriglyceridemia (the resulting condition), but physical inactivity, obesity and other modifiable risk factors remain prevalent.

"Increasing evidence supports triglyceride concentration as a risk factor for cardiovascular disease," the authors write as background information in the article. "If triglyceride concentrations are indeed a risk factor for cardiovascular disease, then it becomes important to establish the prevalence of hypertriglyceridemia in the U.S. population and to learn about the degree of pharmacologic management of this risk factor."

Earl S. Ford, M.D., M.P.H., and colleagues at the Centers for Disease Control and Prevention, Atlanta, examined data for 5,610 participants age 20 or older who participated in the National Health and Nutrition Examination Surveys between 1999 and 2004. The 2,837 men and 2,773 women were interviewed at home and then invited to attend a mobile examination center, where they answered additional questions, underwent examinations and provided blood samples.

A total of 33.1 percent of participants had a triglyceride concentration of 150 milligrams per deciliter or higher (between 150 and 199 milligrams per deciliter is defined as borderline high by the 2001 National Cholesterol Education Program report), 17.9 percent had a concentration of 200 milligrams per deciliter or higher (defined as high), 1.7 percent had a concentration of 500 milligrams per deciliter or higher and 0.4 percent had a concentration of 1,000 milligrams per deciliter or higher.

Compared with those who did not have hypertriglyceridemia, those who did were more likely to be older, be white, have not pursued an education beyond high school, smoke, be overweight or obese or have diabetes. "An important approach to the patient with hypertriglyceridemia is the implementation of non-pharmacological interventions," the authors write. "The high percentages of participants with a triglyceride concentration of 200 milligrams per deciliter or higher who were overweight or obese, who failed to engage in physical activity for approximately 150 minutes per week or who smoked attest to the challenge confronting health care providers in working with their patients to implement therapeutic lifestyle changes."

A total of 1.3 percent of participants used one of three prescription medications (fenofibrate, gemfibrozil or niacin) that treat hypertriglyceridemia, including 2.6 percent of those with a concentration of 150 milligrams per deciliter or higher and 3.6 percent of those with a concentration of 200 milligrams per deciliter or higher. This may reflect uncertainty about the need to treat this abnormality, the authors note. The benefits of pharmacotherapy are clear for patients with levels of 500 milligrams per deciliter or higher, who are at risk for pancreatitis, but therapeutic lifestyle changes remain the initial therapy of choice for those with levels between 200 and 500 milligrams per deciliter.

"As research clarifies uncertainties in the relation between triglyceride concentration and cardiovascular disease, guidelines to treat hypertriglyceridemia will likely be modified," they conclude.


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal Reference:

  1. Earl S. Ford, MD, MPH; Chaoyang Li, MD, PhD; Guixiang Zhao, MD, PhD; William S. Pearson, PhD; Ali H. Mokdad, PhD. Hypertriglyceridemia and Its Pharmacologic Treatment Among US Adults. Arch Intern Med, 2009;169(6):572-578 [link]

Cite This Page:

JAMA and Archives Journals. "High Triglyceride Levels Common, Often Untreated Among Americans." ScienceDaily. ScienceDaily, 30 March 2009. <www.sciencedaily.com/releases/2009/03/090323161117.htm>.
JAMA and Archives Journals. (2009, March 30). High Triglyceride Levels Common, Often Untreated Among Americans. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2009/03/090323161117.htm
JAMA and Archives Journals. "High Triglyceride Levels Common, Often Untreated Among Americans." ScienceDaily. www.sciencedaily.com/releases/2009/03/090323161117.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins